4.8 Letter

Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 384, 期 6, 页码 581-583

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2031717

关键词

-

向作者/读者索取更多资源

Two patients developed severe refractory autoimmune colitis after cancer treatment with immune checkpoint inhibitors, but responded well to a course of subcutaneously administered ustekinumab, an antibody that blocks interleukin-12/23 signaling.
Two patients in whom severe refractory autoimmune colitis developed after cancer treatment with immune checkpoint inhibitors had a response to a course of subcutaneously administered ustekinumab, an antibody that blocks interleukin-12/23 signaling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据